Title : Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease.

Pub. Date : 2021 Dec 15

PMID : 34762934






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 GSK3335103 was shown to engage with the alphavbeta6 integrin and inhibit the activation of TGFbeta in both ex vivo IPF tissue and in a murine model of bleomycin-induced lung fibrosis, as measured by alphavbeta6 engagement, TGFbeta signalling and collagen deposition, with a prolonged duration of action observed in vivo. Bleomycin transforming growth factor alpha Mus musculus